GS Group accelerates investments in healthcare and pharma Korean conglomerate explores future growth opportunities in bio sector
Translated by Ryu Ho-joung 공개 2021-10-05 08:04:24
이 기사는 2021년 10월 05일 08:01 thebell 에 표출된 기사입니다.
GS Group is speeding up investments in the healthcare and pharmaceutical industries after its acquisition of botox maker Hugel, as the South Korean conglomerate is looking for future growth drivers in bio technology.GS Holdings, the conglomerate’s holding company, put additional money into a fund of Seoul-based startup accelerator Bluepoint Partners in August, according to industry sources, bringing the company’s overall investment in the fund to 3 billion won ($2.5 million), which represents 25% of the fund’s total size.
Part of the company’s commitment in the fund was used earlier this year to invest in two bio-tech startups, including CutisBio, which specializes in developing treatments in skin aging and skin cancer as well as functional cosmetics ingredients.
GS Group invests in the bio sector mostly through funds. Four funds have so far received commitments from the conglomerate. Apart from Bluepoint, GS Group invested a total of 1.84 billion won in venture capital firm LSK Investment’s third fund earlier this year, with its commitments representing 7.27% of the fund’s total value.
In March, GS Group put 1 billion won into CBC Group’s fund, C-Bridge healthcare Fund V. The Singapore-headquartered investment firm, focused on bio and healthcare companies across Asia, is part of the GS-led consortium which won the bidding war for Hugel in August.
The conglomerate also invested 1 billion won in venture capital firm Intervest’s fund. The amount represents 4.6% of the fund’s total size.
GS Group still maintains its conservative investment policy, but the recent investments in the bio space signals a clear change in its attitude, industry watchers said. The conglomerate intends to continue to explore investment opportunities in bio-tech startups.
GS Holdings plans to establish a corporate venture capital fund later this year to accelerate investing in the bio space. To that end, the company revised its articles of incorporation to add financial services to its business purpose at this year’s general meeting in March. (Reporting by Ah-kyoung Lee)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감
- 젬백스링크, 포니 자율주행자동차 국내 도입
- 더테크놀로지, 전략 수집 RPG '리버스 삼국' 출시
- [ICTK road to IPO]빅테크 고객사들이 상장 청원한 사연은